Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.74 USD
-2.27 (-2.03%)
Updated May 15, 2024 04:00 PM ET
After-Market: $109.76 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.74 USD
-2.27 (-2.03%)
Updated May 15, 2024 04:00 PM ET
After-Market: $109.76 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
Wall Street Analysts Think Jazz (JAZZ) Could Surge 54.74%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Jazz (JAZZ) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Uncover Value Opportunities With These 5 Earnings Yield Gems
by Rimmi Singhi
Unlock hidden value and drive higher returns to your portfolio with high earnings yield stocks like PLAY, URBN, KELYA, LTHM and JAZZ.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
by Zacks Equity Research
Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -7.28% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 0% and 23.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 12.37% and 52.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.
Jazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
by Zacks Equity Research
Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.
Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Jazz (JAZZ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.